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Introduction
Human papillomaviruses (HPVs) are a group of small,
double-stranded, circular, deoxyribonucleic acid (DNA)
viruses. Although epidemiologic and laboratory data
suggest that cervical cancer typically arises from a series
of causal steps, the main step of malignant trans-
formation in cervical cancer is either associated with or
can be attributed to genital HPV infection [1]. From
more than 74 different types of HPVs isolated so far, at
least 27 have neoplastic potential, especially types 16
and 18 [2].
Cervical cancer is one of the leading malignancies in
women. It has been shown that radiotherapy can reduce
the tumor volume and increase the disease-free survival
rate in cervical cancer [3,4]. The mechanisms and effects
of ionizing radiation include direct damage to DNA and
ribonucleic acid (RNA), chromosomal aberrations, and
disruption of the nucleotide bonds in tumor cells. Current
knowledge regarding the natural history of HPV infection
in cervical cancer following radiotherapy is limited.
Therefore, this study attempted to evaluate the HPV
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status following radiotherapy, for a better understanding
of the effects of ionizing radiation on HPV DNA se-
quences, and any clinical significance it may carry.
This clinical study purports to determine changes in
the presence of HPV subtypes in cervical cancer tissues
before and after radiotherapy, and the relationship
between HPV type and clinical features of the tumors.
We report the results of using the polymerase chain
reaction (PCR) to assess the presence of the DNA
sequences of HPV types 16 and 18 in cervical cancer
tissues both before and after radiotherapy.
Materials and Methods
This study included 58 patients with International
Federation of Gynecology and Obstetrics (FIGO) stage
IIb to IIIb cervical cancer, who were diagnosed and
treated with radiotherapy at Chang Gung Memorial
Hospital, Taiwan, from December 1991 to June 1996.
The patients had had no chemotherapy before radiothe-
rapy to avoid cytotoxic effects on cellular DNA. Patients
were excluded from this study if complications or medical
problems warranted suspension of radiotherapy.
We performed HPV DNA type 16 and 18 tests in
cervical specimens before and after radiotherapy using
PCR. To determine the presence of HPV DNA in the
cervix before radiotherapy, cervical specimens were
obtained at diagnosis by cervical biopsy. To test for the
presence of HPV DNA in the cervix after radiotherapy,
specimens were collected with a sterile wooden spatula
applied to the cervix and vaginal fornix 6 months after
the completion of radiotherapy. Cervical specimens
were also collected from biopsy of any suspected lesion
after radiotherapy.
Procedures for the amplification and subsequent
detection of HPV-16/18 DNA in clinical specimens
have previously been described [5,6]. Sequences and
locations of the 5’ end base of oligonucleotide primers
for the first round and nested amplification of the E6
gene for HPV type 16 were (from the 5’ end):
GAACTGCAATGTTTCAGGACC (96 nucleotides, nt)
and CGTGTTCTTGATGATCTGC (540 nt); and
CAATGTTTCAGGACCCACAGG (102 nt) and
GCAACAAGACATACATCGACCG (523 nt), respec-
tively. The corresponding information for the ampli-
fication of the E6 gene for HPV type 18 consisted of
CACACCACAATACTATGGCGCGCT (91 nt) and
CTCGTGACATAGAAGGTCAACCGG (676 nt); and
TGAGGATCCAACACGGCGACCCTA (116 nt) and
ATTTCATTTTGGGGCTCTAAATGC (651 nt), respective-
ly. The lengths of the final amplified HPV types 16 and
18 DNA were 422 and 536 base pairs (bp), respectively.
The procedures for external beam radiotherapy and
intracavitary brachytherapy have also been described
earlier [7]. A dose of 4,400 cGy was delivered in 22 equal
fractions over 30 to 35 days. This was followed by six
courses of intracavitary brachytherapy 1 to 2 weeks after
external beam radiotherapy. Treatment was given by
employing a remote control after-loading system
to provide 350 cGy at point A for each session of
intracavitary brachytherapy.
Tumor response to radiotherapy was evaluated 4
months after completion of therapy by physical
examination and abdominopelvic computed tomo-
graphy. The definitions for tumor response were based
on World Health Organization (WHO) criteria [8]. Pa-
tients were followed-up every 4 months during the first 2
years after treatment, and every 6 months thereafter.
Statistical analysis
The association of tumor response with HPV status and
the risk of cancer recurrence were determined by Fisher’s
exact test. Differences in survival rates were assessed by
the log-rank test. A p value below 0.05 was regarded as
indicating a significant difference.
Results
In total, 58 cervical cancer patients were included in the
study, and all were eligible for the follow-up evaluation.
The mean age was 51 years (range, 31–71 years). The
FIGO stage distribution was: stage IIb in 25 patients,
stage IIIa in 6, and stage IIIb in 27. Twelve cancers were
well differentiated, 24 were moderately differentiated,
and 22 were poorly differentiated. Fifty cancers were
squamous cell carcinoma, and 8 were adenocarcinoma.
The median follow-up period was 5.1 years (range, 3.2–
6.5 years).
Before radiotherapy, HPV-16 was present in 42 pa-
tients (72.4%), HPV-18 in 12 (20.7%), and HPV-16/18
was negative in 4 (6.9%). After radiotherapy, HPV-16
was found in 26 patients (44.8%), HPV-18 in 7 (12.1%),
and HPV-16/18 was negative in 25 (43.1%). There were
no double infections by HPV-16 and HPV-18. Of the 54
HPV-16/18-positive cases before radiotherapy, the HPV
DNA had disappeared after radiotherapy in 21 cases.
The remaining 33 patients with tumors containing HPV
DNA prior to radiotherapy had continued presence of
the same genotype of HPV DNA after radiotherapy.
None of the HPV-negative cervical tumors became
positive following radiotherapy.
The relationships between HPV DNA status and
various clinicopathologic factors, including large tumor
size, parametrium status, stage, metastasis to pelvic
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lymph nodes, non-squamous or grade III histology, and
age, are shown in Table 1. No statistical correlation
between HPV DNA status and stage, histologic grade,
tumor size, parametrium status, age, or pelvic lymph
node metastasis was observed. However, histology was
significantly associated with HPV genotype (p = 0.02).
HPV-16 was predominant among squamous cell
carcinomas (38/42, 90.5%), whereas HPV-18 only oc-
curred frequently in adenocarcinomas (5/12, 41.7%).
The overall response rate of cervical cancer patients
after radiotherapy was 82.8% (48/58), including
complete responses in 42 cases (72.4%) and partial
responses in six (10.3%). The presence of HPV-16/18
DNA and tumor responses to radiotherapy are
summarized in Table 2. The tumor response rates of
cervical carcinoma after radiotherapy in patients with
tumors containing HPV-16 DNA, HPV-18 DNA, and no
detectable HPV-16/18 DNA sequences were 92.9%,
50%, and 75%, respectively. The presence of HPV-16
DNA in tumors treated with radiotherapy was signi-
ficantly associated with a favorable response compared
to HPV-18-positive tumors (p = 0.002).
Of the 42 patients with a complete response to
radiotherapy, one patient had local recurrence and two
patients developed distant metastasis. Among them,
one patient died within 47 months after radiotherapy
followed by adjuvant chemotherapy. Of the six patients
with partial response, one patient had local recurrence,
and one died within 39 months after radiotherapy due
to lung metastasis. Of the 10 patients with a poor
response, four patients had progressive local diseases
and another four developed distant metastasis. Among
them, seven patients died of diseases within 12 to 41
months in spite of attempts at salvage management
with exenteration or combined operation and radio-
therapy. Overall, the 5-year disease-free survival rate of
the entire group was 77.6% (45/58), with a median
survival of 49 months.
The 5-year disease-free survival rate in patients
with tumors containing HPV-16 DNA, HPV-18 DNA,
and no detectable HPV-16/18 DNA are listed in Table
3. After a median follow-up of 5.1 years (range, 3.2–
6.5 years), patients with HPV-18-positive tumors were
found to have a significantly higher relapse rate than
patients with HPV-16-positive tumors (6/12, 50% vs
6/42, 14.3%, p = 0.02).
Discussion
The effect of ionizing radiation on HPV DNA and RNA
sequences in cervical cancer remains unknown. To date,
Table 1. Relationship between human papillomavirus (HPV) DNA status and various clinicopathologic parameters
in cervical cancer patients
Characteristics HPV-16 positive (n = 42) HPV-18 positive (n = 12) HPV-16/18 negative (n = 4)
Age (yr)
< 50 16 7 1
≥ 50 26 5 3
Stage
IIb 20 2 0
IIIa 2 4 1
IIIb 20 6 3
Grade
I 10 2 0
II 17 5 1
III 15 5 3
Histology
Squamous cell carcinoma 38 7 2
Adenocarcinoma 4 5 2
Tumor size (cm)
< 4 23 5 1
≥ 4 19 7 3
Parametrium invasion
Unilateral 22 8 1
Bilateral 20 4 3
Pelvic lymph nodes
Negative 28 7 2
Positive 14 5 2
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only a few studies have evaluated the effect of
radiotherapy on the continued presence of HPV DNA
sequences in cervical cancer tissues [9]. Our study
demonstrates that the presence of HPV DNA can be
identified in all recurrent or persistent cervical cancer
tumors that were also positive for HPV-16/18 DNA
before radiotherapy, and that none of the HPV-negative
cervical tumors before radiotherapy became positive
following radiotherapy. Our study reveals that the effect
of ionizing radiation did not significantly alter the
identification of the continued presence of HPV DNA
sequences in these tissues.
Published reports on the prognostic significance of
the presence of HPV DNA in cervical cancer are
controversial. Several reports have suggested that
patients with HPV-18-positive tumors have a worse
prognosis than patients with HPV-16 DNA in their
tumors [10–13]; other reports have suggested that pa-
tients with no detectable HPV in their tumors have a
worse prognosis than those with HPV-positive tumors
[14,15]; and still other reports have shown no asso-
ciation between the presence or type of HPV with the
prognosis [16,17]. This study, in agreement with those
of Burger et al [10] and Nakagawa et al [11], suggests
that cervical cancer patients with HPV-18-positive
tumors have a significantly higher relapse rate and a
worse disease-free survival rate than patients with HPV-
16-positive tumors.
Regarding tumor response following radiotherapy,
some reports have shown that radio-responsiveness is
one of the most potent predictors of survival [18]. To
date, a clear relationship between HPV genotype and
radiation response is limited. Results of the present
study suggest that patients with HPV-18-positive tumors
are significantly associated with a poor tumor response
following radiotherapy compared to patients with
HPV-16-positive tumors. This implies that the identifi-
cation of HPV genotypes in cervical carcinoma may play
a valuable role in predicting tumor response to
radiotherapy. From this viewpoint, it is important that
new pretreatment markers are identified in cervical
cancer prior to radiotherapy, so that patients who are
likely to be poor respondents to radiotherapy can receive
other therapy that may be more effective. From the
results of our study, such an identification may be
worthwhile in HPV-18-positive cervical cancer. How-
ever, our sample size was limited, and multivariate
analysis failed to reveal any significance in the relation-
ship between HPV genotype and lymph node metastasis
and tumor size. Thus, we need to collect more cases
for inclusion into our study in order to investigate
the relationship between HPV genotype and lymph
node metastasis and tumor size.
Although the underlying mechanisms for the biologic
potential of HPV subtypes are not well understood, it is
possible that the poor tumor response to radiotherapy
in HPV-18-positive tumors may indicate that HPV-18-
positive tumors have radio-resistant characteristics that
lead to a higher clinical relapse rate and a worse prog-
nosis. Further study is required to confirm the hypothesis
of a biologic mechanism in HPV-18-related cervical
cancer.
Several clinicopathologic factors which predict a
poor prognosis in patients with cervical carcinoma,
including large tumor size, parametrial extension of
disease, and metastasis to pelvic lymph nodes, have
been well established [19,20]. In this study, these clini-
copathologic characteristics were analyzed in relation
to the HPV type detected; no significant differences
among the parameters were observed. Although Chen
Table 2. Human papillomavirus (HPV) DNA status and tumor response to radiotherapy
HPV status Total Complete response Partial response Stable disease Progressive disease Response rate
n n n  n  n (%)
HPV-16 positive 42 34 5 3 0 92.9
HPV-18 positive 12 6 0 5 1 50.0
HPV-16/18 negative 4 2 1 1 0 75.0
Total 58 42 6 9 1 82.8
Table 3. Human papillomavirus (HPV) DNA status and 5-year disease-free survival rate
HPV status Total No evidence of disease Alive with disease Died of disease 5-year disease-free
n n n n survival rate (%)
HPV-16 positive 42 36 1 5 85.7
HPV-18 positive 12 6 2 4 50.0
HPV-16/18 negative 4 2 1 1 50.0
Total 58 44 4 10 75.9
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et al [17] and Girardi et al [21] showed that HPV-
positive tumors spread to pelvic lymph nodes significantly
more often than did HPV-negative tumors, no significant
difference was observed in our study. However, this
study, in agreement with the studies of Nakagawa et al
[11] and Rose et al [12], suggests that the HPV-16
genotype occurs more commonly in squamous tumors,
whereas the HPV-18 genotype occurs relatively frequently
in glandular tumors.
In conclusion, the results suggest that cervical can-
cer patients with HPV-18 DNA in their tumors have
a significantly poorer response to radiotherapy. This
implies that more intensive treatment for patients with
HPV-18-positive tumors is advisable, such as the
combination of chemotherapy and radiotherapy.
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